|
AIDAC Recommends Approval of GSK’s Anti-Anthrax Drug on Resubmission
The FDA’s Anti-Infective Drugs Advisory Committee Friday recommended approval of GlaxoSmithKline’s (GSK) 40-mg/kg raxibacumab IV solution, with or without an antimicrobial, to treat adults infected in an airborne anthrax attack.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives